Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2021

01-05-2021 | Metastasis | Epidemiology

The prognostic significance of metastatic pattern in stage IV male breast cancer at initial diagnosis: a population-based study

Authors: José Pablo Leone, MD, Bernardo Amadeo Leone, Ariel O. Zwenger, Carlos Teodoro Vallejo, Alberto Omar Romero, Mario Raúl Machiavelli, Juan Eduardo Pérez, Julieta Leone

Published in: Breast Cancer Research and Treatment | Issue 1/2021

Login to get access

Abstract

Purpose

Metastatic pattern (MP) is a prognostic factor in women with breast cancer. However, the prognostic significance of MP in male breast cancer patients remains unknown.

Methods

Using the SEER database, we gathered demographic information and disease characteristics for men diagnosed with de novo metastatic breast cancer from 2010 to 2017. Metastases to bone, brain, liver, and lung were used to define MP (bone-only, visceral, bone and visceral [BV], or other). Statistical analyses were performed to identify associations between overall survival (OS) and MP, as well as other patient and tumor features. We used multivariate logistic regression to evaluate factors associated with sites of metastases.

Results

We included 250 patients. MP distribution was bone = 38.8%, visceral = 14.8%, BV = 33.2%, and other = 13.2%. Median OS for each was bone = 33 months, visceral = 23 months, BV = 20 months, and other = 46 months (p = 0.046). Patients with brain metastases had significantly shorter OS compared with no brain metastases (median OS = 9 months vs. 30 months; p < 0.001). Compared with other subtypes, triple negative had the shortest OS (median 9 months, p < 0.001). Logistic regression modeling revealed that compared with HR+/HER2− breast cancers, HR−/HER2+ had higher odds of liver metastases and triple negative had higher odds of brain metastases. Patients younger than 50 years had a significantly greater risk of developing brain metastases.

Conclusions

MP and tumor subtype can predict OS outcomes in men with metastatic breast cancer at diagnosis. Brain metastases confer very poor prognosis.
Literature
4.
go back to reference Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ (1999) An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 126(4):775–780; discussion 780–771CrossRef Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ (1999) An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 126(4):775–780; discussion 780–771CrossRef
7.
go back to reference Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schroder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Lago LD, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litiere S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH (2018) Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol 29(2):405–417. https://doi.org/10.1093/annonc/mdx651CrossRefPubMed Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schroder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Lago LD, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litiere S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH (2018) Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol 29(2):405–417. https://​doi.​org/​10.​1093/​annonc/​mdx651CrossRefPubMed
9.
go back to reference Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, Plichta JK, Ricker C, Roshal A, Ruddy KJ, Safer JD, Van Poznak C, Yung RL, Giordano SH (2020) Management of male breast cancer: ASCO guideline. J Clin Oncol:JCO1903120. https://doi.org/10.1200/JCO.19.03120 Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, Plichta JK, Ricker C, Roshal A, Ruddy KJ, Safer JD, Van Poznak C, Yung RL, Giordano SH (2020) Management of male breast cancer: ASCO guideline. J Clin Oncol:JCO1903120. https://​doi.​org/​10.​1200/​JCO.​19.​03120
10.
go back to reference Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Perez JE, Machiavelli M, Rodriguez R, Alvarez LA (1988) Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The GOCS (Grupo Oncologico Cooperativo del Sur) experience. Am J Clin Oncol 11(6):618–622CrossRef Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Perez JE, Machiavelli M, Rodriguez R, Alvarez LA (1988) Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The GOCS (Grupo Oncologico Cooperativo del Sur) experience. Am J Clin Oncol 11(6):618–622CrossRef
23.
Metadata
Title
The prognostic significance of metastatic pattern in stage IV male breast cancer at initial diagnosis: a population-based study
Authors
José Pablo Leone, MD
Bernardo Amadeo Leone
Ariel O. Zwenger
Carlos Teodoro Vallejo
Alberto Omar Romero
Mario Raúl Machiavelli
Juan Eduardo Pérez
Julieta Leone
Publication date
01-05-2021
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2021
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-06052-z

Other articles of this Issue 1/2021

Breast Cancer Research and Treatment 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine